# A Clinical Study on the Safety and Tolerability of PL54 Injection in Adult Patients With Phenylketonuria (PKU)

> **NCT07672756** · PHASE1 · RECRUITING · sponsor: **Chongqing Peg-Bio Biopharm Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Phenylketonuria (PKU)

## Interventions

- **BIOLOGICAL:** PL54

## Key facts

- **NCT ID:** NCT07672756
- **Lead sponsor:** Chongqing Peg-Bio Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-20
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07672756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07672756, "A Clinical Study on the Safety and Tolerability of PL54 Injection in Adult Patients With Phenylketonuria (PKU)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07672756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*